Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant nivolumab after preoperative DCF and R0 resection for non-pCR locally advanced esophageal cancer
jRCT1031220223Phase 2Recruiting
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in esophageal cancer and esophagogastric junction cancer. Primary endpoint: 2-year disease-free survival rate. Started Jul 2022; status: recruiting.
02
Drugs
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on jRCT1031220223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031220223.